Molecular diagnostics company RedPath Integrated Pathology, Inc., points us at results from The National Pancreatic Cyst Registry, showing that integrated molecular pathology using PathFinderTG can improve accuracy when determining the malignant potential of pancreatic cysts.
RedPath’s patented PathFinderTG Pancreas profile uses LOH markers, oncogene mutations, and DNA content abnormalities to evaluate pancreatic cystic lesions and integrate these analyses with clinical features to accurately risk stratify patients for the development of pancreatic adenocarcinoma.
A newly published multicenter clinical study has been published online in Endoscopy here. It reviewed disease outcomes in 492 patients who had PathFinderTG testing as part of their standard of care when cytological analysis of cyst fluid was not definitive for the presence of malignancy. The study concluded that integrated molecular pathology using PathFinderTG more accurately determines malignant potential of pancreatic cysts than current guideline-recommended criteria. This can help guide subsequent patient management decisions for surgery and surveillance.
The results show that PathFinderTG is the most accurate, clinically validated test available for determining risk of malignancy in pancreatic cysts. PathFinderTG could distinguish patients who had 97% probability of benign disease at 3 years follow-up from those who were at 31-76 fold greater risk of malignancy. This is a marked improvement in risk stratification over that of current guideline-recommended criteria.
“We are extremely pleased to have such positive data on our PathFinderTG test published,” said Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology. “These results clearly demonstrate the importance of PathFinderTG when it comes to managing pancreatic cyst patients.”
Source: RedPath Integrated Pathology, Inc.